drugset / Trial / NCT06733402

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris

NCT06733402

Phase 1 Completed 1000 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

To demonstrate the efficacy, therapeutic equivalence and safety of Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and US Reference Listed Drug, Canadian Reference Product over the placebo control in the treatment of acne vulgaris.

Timeline

Start
2024-06-20
Primary completion
2024-06-20
Completion
2024-11-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Trifarotene Small molecule 0.005 % Topical

Indications